Dyshidrotic eczema associated with the use of IVIg.

Abstract

Intravenous immunoglobulin (IVIg) treatment is highly effective for autoimmune diseases including myasthenia gravis. Recovery is observed at approximately. 75% of myasthenia gravis patients through IVIg treatment. As a result of many clinical studies, the recommended dose is determined as 0.4 g/kg for 5 days (maximum total dose at 2 g/kg body weight). If an additional immunomodulatory treatment is not administered, IVIg maintenance treatment is needed mostly. However, some side effects may inhibit long-term treatment. For this reason, it is important to know the effect profile well and when the treatment should be discontinued. A female myasthenia gravis patient case is presented here, where dyshidrotic eczema has occurred after the second dose of  intravenous Ig medication and whose treatment is despite further IVIg therapy.

• Authors: Dilcan Kotan, Teoman Erdem, Bilgehan Atilgan Acar, Ayhan Boluk
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2013 (Feb 15 2013) ISSN: 1757-790X [Electronic] England
• PMID: 23417935 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulins, Intravenous
• Immunologic Factors

Topics

• Adult
• Diagnosis, Differential
• Eczema, Dyshidrotic (chemically induced, diagnosis)
• Female
• Humans
• Immunization, Passive (adverse effects)
• Immunoglobulins, Intravenous (administration & dosage, adverse effects)
• Immunologic Factors (administration & dosage, adverse effects)
• Myasthenia Gravis (drug therapy)